For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Cellular Peptide
PT-141
A cyclic seven-amino-acid melanocortin agonist studied in clinical research for its activity at the MC3R and MC4R receptors.
Quantity
$29.99
Bundle & save
Delivery
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2–3 business days
Overnight shipping available
Free shipment protection included
PT-141
1 × 10mg · $29.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
Certificate of Analysis
Third-party tested · Independent analytical lab
10mg
99.02%latest
| Tested | Measured | Purity |
|---|---|---|
| Jun 2026 | 11.21mg | 99.02% |
| Jun 2026 | 11.58mg | 99.77% |
| May 2026 | 11.73mg | 99.71% |
| Mar 2026 | 13.62mg | 99.70% |
| Feb 2026 | 11.86mg | 99.86% |
| Jan 2026 | 10.03mg | 99.71% |
| Dec 2025 | 10.66mg | 99.73% |
| Nov 2025 | 10.71mg | 99.81% |
Frequently researched together
Commonly studied alongside PT-141.
Compound information
Technical specifications
Molecular profile
| Type | Cyclic heptapeptide |
| CAS number | 189691-06-3 |
| Molecular weight | 1025.2 g/mol |
| Amino acids | 7 |
| Sequence | Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Formula | C50H68N14O10 |
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Sources & references
Peer-reviewed literature, for research context
- Obstetrics & Gynecology
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
2019·DOI: 10.1097/AOG.0000000000003500·PMID: 31599840Kingsberg SA, Clayton AH, Portman D, et al.
View source - International Journal of Impotence Research
PT-141: a melanocortin agonist for the treatment of sexual dysfunction
2004·PMID: 12851303Diamond LE, Earle DC, Rosen RC, et al.
View source - Journal of Sexual Medicine
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
2006·DOI: 10.1111/j.1743-6109.2006.00268.x·PMID: 16839319Diamond LE, Earle DC, Heiman JR, et al.
View source - Journal of Women's Health
Reported Event Profile of Bremelanotide Across the Clinical Development Program
2022View source - Neurology International
Bremelanotide for Treatment of Female Hypoactive Sexual Desire
2022·DOI: 10.3390/neurolint14010006·PMID: 35076581View source
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.